Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries

Abstract

Purvish M. Parikh

Cancer-associated anemia (CAA) remains a major unmet need that compromises overall survival (OS) and quality of life (QoL). Currently, available guidelines do not take into consideration the unique challenges in low- and middle-income countries (LMIC). Our CAA patients have to battle preexisting impaired nutritional status, depleted body iron stores, financial limitations, and difficulty in having easily accessible affordable healthcare. Hence, we fulfilled the need of guidelines for LMIC. A group of subject experts were put together, given background literature, met in a face-to-face discussion, voted using Delphi process, and finally agreed on the contents of this guideline document. As many as 50% of cancer patients will have significant anemia (hemoglobin < 10 g/dL) at initial diagnosis. It is most commonly seen with gastrointestinal malignancies, head and neck cancers, and acute leukemias. The hemoglobin falls further after initiation of cancer directed therapy, due to chemotherapy itself or heightened nutritional deficiency. Its evaluation should include tests for complete blood count, red blood cell morphology, reticulocyte count, Coombs test, and levels of vitamin B12 and folic acid. Iron status should be monitored using test to measure serum iron, total iron binding capacity, transferring saturation, and serum ferritin levels. A minimum of 50% of cancer patients with anemia require iron supplements. The preferred mode of therapy is with intravenous (IV) iron using ferric carboxymaltose (FCM). Most patients respond satisfactorily to single dose of 1000 mg. It is also safe and does not require use of a test dose. Significant anemia is found in at least half of all cancer patients in India, South Asian Association for Regional Cooperation region, and other LMIC countries. Its awareness among healthcare professionals will prevent it from remaining undiagnosed (in up to 70% of all cancer patients) and adversely affecting OS and QoL. The benefits of treating them with IV iron therapy are quick replenishment of iron stores, hemoglobin returning to normal, better QoL, and avoiding risk of infections/reactions with blood transfusions. Many publications have proven the value of single-dose FCM in such clinical situations. CAA has been proven to be an independent prognostic factor that adversely affects both QoL and OS in cancer patients. Use of FCM as single IV dose of 1000 mg is safe and effective in the majority of patients with CAA.

Keywords

iron deficiency - ferric carboxymaltose - erythropoietin - quality of life - well-being

• References:

• 1 Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15 (06) 979-986
• 2 Prabhash K, Nag S, Patil S, Parikh PM. Optimising management of cancer related anemia. Indian J Cancer 2011; 48 (01) 1-10
• 3 Barrett-Lee PJ, Ludwig H, Birgegård G. et al; European Cancer Anaemia Survey Advisory Board and Participanting Centers. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006; 70 (01) 34-48
• 4 Birgegård G, Aapro MS, Bokemeyer C. et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68 (Suppl. 01) 3-11
• 5 Bremberg ER, Brandberg Y, Hising C, Friesland S, Eksborg S. Anemia and quality of life including anemia-related symptoms in patients with solid tumors in clinical practice. Med Oncol 2007; 24 (01) 95-102
• 6 Biswas G, Pandey A, Ghadyalpatil N. et al. Role of Cresp^® in the management of chemotherapy-induced anemia in cancer patients: a real-world clinical practice audit. South Asian J Cancer 2020; 9 (01) 59-61
• 7 Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104 (08) 2263-2268
• 8 Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96 (03) 823-833
• 9 Sundriyal D, Nayak PP, Arya L, Walia M, Saha R. Evaluation of iron status in patients of solid organ malignancies: study from a cancer research centre. Indian J Surg Oncol 2020; 11 (01) 56-59
• 10 NCCN 2011 guidelines. Zugriff am 24. Juni 2023 unter: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
• 11 Revicki DA, Brown RE, Feeny DH. et al. Health-related quality of life associated with intravenous iron in patients with cancer-associated anemia. Oncologist 2007; 12 (06) 741-749
• 12 Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91 (12) 2214-2221
• 13 Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of I.V. iron. Ann Oncol 2012; 23 (08) 1954-1962
• 14 Aapro M, Beguin Y, Bokemeyer C. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2021; 32 (04) 508-521
• 15 Gafter-Gvili A, Steensma DP, Auerbach M. Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?. J Natl Compr Canc Netw 2014; 12 (05) 657-664
• 16 Aapro M, Beguin Y, Bokemeyer C. et al; on behalf of the ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer. . ESMO Clinical Practice Guidelines. Annals of Oncology 2018; 29 (Suppl. 04) 96-110
• 17 Hufnagel DH, Mehta ST, Ezekwe C, Brown AJ, Beeghly-Fadiel A, Prescott LS. Prevalence of anemia and compliance with NCCN guidelines for evaluation and treatment of anemia in patients with gynecologic cancer. J Natl Compr Canc Netw 2021; 19 (05) 513-520
• 18 Link H, Schmitz S. Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany. Onkologie 2013; 36 (05) 266-272
• 19 Reeves DJ, Quebe AK, Patel R. The ESA APPRISE Oncology Program: a history of REMS requirements, a review of the data, and an approach to compliance in the hospital. P&T 2011; 36 (07) 423-433
• 20 Aggarwal S, Vaid A, Ramesh A. et al. Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling. South Asian J Cancer 2018; 7 (02) 96-101
• 21 Parikh PM, Narayanan P, Vora A. et al. Conflict of interest disclosure and interpretation - rest assured the medical professional in the audience is perceptive, alert and smart. Int J Med Sci 2019; 71: 4-8
• 22 Parikh PM, Sharatchandra Hingmire S, Patil B. et al. Oncology Gold Standard™ consensus statement on counselling patients for molecular testing and personalized cancer care. Int J Mol Immuno Oncol 2017; 2: 47-57
• 23 Niederberger M, Spranger J. Delphi technique in health sciences: a map. Front Public Health 2020; 8: 457
• 24 Noronha V, Joshi A, Patil VM. et al. Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents. Asia Pac J Clin Oncol 2018; 14 (02) e129-e137
• 25 Naeim A, Henning DJ, Becker PS. et al. The role of iron in cancer-related anemia: a report from the National Comprehensive Cancer Network Myeloid Growth Factors Panel. J Natl Compr Canc Netw 2021; 19 (01) 1-16
• 26 Parikh PM, Gupta N, Rangarajan B. et al. Real-world use of intravenous iron in cancer patients with iron deficiency anemia: results from the HEMATOCRIT study. Oncologist 2019; 24 (08) 1027-1034
• 27 Bokemeyer C, Aapro MS, Courdi A. et al; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43 (02) 258-270
• 28 Bohlius J, Bohlke K, Castelli R. et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol 2021; 39 (08) 867-883
• 29 Parikh PM, Madkaikar M, Ramanathan P. et al. Safety and efficacy of iron sucrose in patients with cancer-related iron deficiency anemia: a randomized, controlled study. J Clin Oncol 2012; 30 (suppl): Abstract 14014
• 30 Parikh PM, Vora AR, Patel HA. et al. Comparative study of intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in cancer patients on chemotherapy. Indian J Med Paediatr Oncol 2014; 35 (02) 105-109
• 31 Henry DH, Dahl NV, Auerbach MA. Intravenous iron: a critical appraisal of its role in the treatment of iron deficiency anemia and implications for future research. Oncologist 2011; 16 (Suppl. 03) 15-26
• 32 Singh T, Gupta A, Mittal A. et al. Comparative study of intravenous iron sucrose and oral iron in cancer-associated anemia. Indian J Med Paediatr Oncol 2016; 37 (04) 223-226
• 33 Bansal D, Bhakuni DS, Kalaivani M. et al. Comparative study of intravenous iron sucrose and oral iron therapy in the treatment of iron deficiency anemia in cancer patients undergoing chemotherapy. Indian J Med Paediatr Oncol 2017; 38 (03) 287-291f
• 34 Srivastava A, Kumar R, Bhargava R. et al. Evaluation of efficacy and safety of intravenous iron sucrose in patients with cancer-related anemia. Indian J Med Paediatr Oncol 2017; 38 (02) 184-188
• 35 Steinmetz T, Beutel G, Steinmetz AP, Popp FC. Treatment of cancer-associated anemia with intravenous iron: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2021; 147 (05) 1277-1287
• 36 Steinmetz T, Tschechne B, Harlin O. et al. Ferric carboxymaltose in the treatment of iron deficiency anemia in oncology patients: a retrospective observational study. Onkologie 2011; 34 (06) 314-318
• 37 Gasche C, Ahmad T, Tulassay Z. et al. Ferric carboxymaltose for iron deficiency anemia in patients with inflammatory bowel disease: a randomized, controlled trial. Am J Gastroenterol 2013; 108 (05) 753-761
• 38 Reinisch W, Staun M, Tandon RK. et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013; 108 (12) 1877-1888
• 39 Koskenkorva TS, Peltola HT, Kekomäki R. et al. Ferric carboxymaltose administered as a single infusion for iron deficiency anemia in heavy non-menstruating women: a randomized controlled trial. Gynecol Oncol 2015; 137 (01) 107-112
• 40 Talboom K, Borstlap WAA, Roodbeen SX. et al; FIT collaborative group. Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial. Lancet Haematol 2023; 10 (04) e250-e260
• 41 Chardalias L, Papaconstantinou I, Gklavas A, Politou M, Theodosopoulos T. Iron deficiency anemia in colorectal cancer patients: is preoperative intravenous iron infusion indicated? A narrative review of the literature. Cancer Diagn Progn 2023; 3 (02) 163-168
• 42 Kennedy NA, Achebe MM, Biggar P, Pöhlmann J, Pollock RF. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. Int J Clin Pharm 2023; 45 (03) 604-612
• 43 Gluszak C, de Vries-Brilland M, Seegers V. et al. Impact of iron-deficiency management on quality of life in patients with cancer: a prospective cohort study (CAMARA study). Oncologist 2022; 27 (04) 328-333
• 44 Kim HY, Kim HY, Han HS. et al. Efficacy and safety of ferric carboxymaltose for iron-deficiency anemia in patients with gastrointestinal cancer: a randomized, open-label, multicenter study. Ann Oncol 2021; 32 (01) 117-125
• 45 Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in the treatment of iron deficiency anemia. Ther Adv Hematol 2015; 6 (05) 228-237
• 46 Bhandari S, Duggal R, Kumar R, Mishra A, Rastogi N. Intravenous iron in geriatric patients with cancer-associated anemia: an experience from tertiary care center in India. J Geriatr Oncol 2019; 10 (01) 138-140
• 47 Johansson PI, Rasmussen AS, Thomsen LL, Holmboe S, Brinch K, Kehlet H. Intravenous iron supplementation to patients with cancer-related anemia undergoing chemotherapy causes significant improvements in fatigue and quality of life. J Clin Oncol 2001; 19 (21) 3781-3787
• 48 ChatGPT Feb 13 Version. Zugriff am 24. Juni 2023 unter: https://chat.openai.com/chat#:~:text=Open%20sidebar,help%20us%20improve